

Foundation Medicine, Inc. Investor Relations Department 150 Second Street Cambridge, MA 02141 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: FMI	
Last Trade:	42.35
Trade Time:	4:00 PM ET October 17, 2017
Change:	-2.05 🖶 (-4.617%)
Day Range	42.35 - 44.90
52-Week Range	17.10 - 47.35
Volume	124,015
Day Range 52-Week Range	42.35 - 44.9 17.10 - 47.3

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

Foundation Medicine is a commercial-stage company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient's individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company's first clinical product, FoundationOne™, is the only commercially available comprehensive

molecular infor... (more)

## **Stock Performance**



#### Press Releases [View all]

October 16, 2017

Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care

October 12, 2017

Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call

October 10, 2017

<u>Foundation Medicine Appoints Tom Civik as</u> <u>Chief Commercial Officer</u>

October 2, 2017

Foundation Medicine Receives Approval from the State of New York for its
FoundationACT Liquid Biopsy Assay

September 8, 2017

Foundation Medicine to Present Validation
Data for Its Assay Measuring Tumor
Mutational Burden in Blood (bTMB), a New,
Non-Invasive Predictor of Response to
Immunotherapy

## Upcoming Events [View all]

November 1, 2017 4:30 PM ET

Foundation Medicine Third Quarter 2017
Financial Results Conference Call

Nov 16-19, 2017

<u>AONN – Academy of Oncology Nurse &</u> Patient Navigators

## Financials [View all]

Second Quarter Financial Results

March 3, 2017

Annual Report (10-K)

April 28, 2017

Proxy Statement (DEF 14A)

August 1, 2017

Quarterly Report (10-Q)

May 9, 2017

Quarterly Report (10-Q)

November 2, 2016

Quarterly Report (10-Q)